Hajime Uno, PhD
Assistant Professor, Department of Data Sciences and Population Sciences
Hazard ratio (HR) has been routinely used to summarize the treatment effect in almost all cancer clinical trials with time-to-event outcomes. However, there is no universally superior method. HR is not an exception. In this training session, I will talk about issues of HR and introduce several alternative summary measures.